GLOW Blend
Status
No approved product. No FDA-approved labeling exists for any component in injectable form or for the combination. GHK-Cu is regulated in the United States as a cosmetic ingredient for topical use.
What it is
A community blend of GHK-Cu, BPC-157 and TB-500 aimed at skin and repair.
What published research measured
Combines the copper tripeptide GHK-Cu with BPC-157 and the thymosin beta-4 derivative, marketed for skin, hair and connective tissue. The strongest evidence among the three belongs to GHK-Cu, and it is topical evidence — controlled studies of skin applied preparations, not of injection. Injecting a copper-complexed peptide is a materially different proposition from applying it, with no controlled human data behind it, and copper administered systemically has its own toxicology. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.